Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease

Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver di...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology communications 2020-12, Vol.4 (12), p.1758-1768
Main Authors: Huang, Rui, Zhu, Li, Wang, Jian, Xue, Leyang, Liu, Longgen, Yan, Xuebing, Huang, Songping, Li, Yang, Yan, Xiaomin, Zhang, Biao, Xu, Tianmin, Li, Chunyang, Ji, Fang, Ming, Fang, Zhao, Yun, Cheng, Juan, Wang, Yinling, Zhao, Haiyan, Hong, Shuqin, Chen, Kang, Zhao, Xiang‐an, Zou, Lei, Sang, Dawen, Shao, Huaping, Guan, Xinying, Chen, Xiaobing, Chen, Yuxin, Wei, Jie, Zhu, Chuanwu, Wu, Chao
Format: Article
Language:English
Subjects:
Age
Body mass index
Coronaviruses
Diabetes
Hepatitis B
Hypertension
Laboratories
Liver diseases
Lung diseases
Original
Patients
Phosphatase
Severe acute respiratory syndrome coronavirus 2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in patients with COVID‐19 with chronic liver diseases. We described the clinical features in patients with COVID‐19 with nonalcoholic fatty liver disease (NAFLD). Confirmed patients with COVID‐19 from hospitals in 10 cities of Jiangsu Province, China, were retrospectively included between January 18, 2020, and February 26, 2020. The hepatic steatosis index (HSI) was used to defined NAFLD. A total of 280 patients with COVID‐19 were enrolled. Eighty‐six (30.7%) of 280 patients with COVID‐19 were diagnosed as NAFLD by HSI. One hundred (35.7%) patients presented abnormal liver function on admission. The median alanine aminotransferase (ALT) levels (34.5 U/L vs. 23.0 U/L; P 40 U/L) (40.7% vs. 10.8%; P 
ISSN:2471-254X
2471-254X
DOI:10.1002/hep4.1592